United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.
You may also be interested in...
‘Manual’ Labor May Boost Inhaled Remodulin’s Chances
United Therapeutics hopes plainer instructions will alleviate doctor and patient worry over tricky device-drug combination.
‘Manual’ Labor May Boost Inhaled Remodulin’s Chances
United Therapeutics hopes plainer instructions will alleviate doctor and patient worry over tricky device-drug combination.
Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.